CoChat

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Published version of a preprint

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab, the two currently approved type I CD20 antibodies. The three antibodies were compared in assays measuring direct cell death (AnnexinV/PI staining and time-lapse microscopy), complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), and internalization. The models used for the comparison of their activity in vivo were SU-DHL4 and RL xenografts. GA101 was found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it was 10 to 1,000 times less potent in mediating CDC. GA101 showed superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and was comparable with these two in ADCP. GA101 also showed slower internalization rate upon binding to CD20 than rituximab and ofatumumab. In vivo, GA101 induced a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. When rituximab-pretreated animals were used, second-line treatment with GA101 was still able to control tumor progression, whereas tumors escaped rituximab treatment. Taken together, the preclinical data show that the glyoengineered type II CD20 antibody GA101 is differentiated from the two approved type I CD20 antibodies rituximab and ofatumumab by its overall preclinical activity, further supporting its clinical investigation.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-1182

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. Engelberts, 2010, Ofatumumab targets a conformational membrane-proximal epitope which contains amino acids located in the small and large loops of CD20, Haematol-Hematol J, 95, 46
  2. Beurskens, 2010, NK cell binding and induction of potent NK cell-mediated ADCC by ofatumumab, a new human CD20 monoclonal antibody [abstract], Haematologica, 95, 173

Cited by

See all 380

Metadata

Authors
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M. N., Reslan, L., Gerdes, C. A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., Niederfellner, G., Bacac, M., & Klein, C.
Affiliations
  • F. Hoffmann-La Roche AG (CH)
  • Authors' Affiliations: 1Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Cancérologie de Lyon, Institut National de la Santé et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France
  • Lyon 1 Université (FR)
Venue
Molecular Cancer Therapeutics
Published
2013-10-01
Volume
12
Issue
10
Pages
2031-2042
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2135802989
Cited by
366
References
39
Citations by year
2026: 18 · 2025: 31 · 2024: 20 · 2023: 24 · 2022: 27 · 2021: 26 · 2020: 24 · 2019: 34 · 2018: 28 · 2017: 34 · 2016: 29 · 2015: 41 · 2014: 23 · 2013: 3
FWCI
23.92
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Roche Innovation Center Zurich
  • University of Leicester
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
obinutuzumab, rituximab, ofatumumab, anti-CD20 monoclonal antibody, glycoengineering, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, B-cell depletion, antibody internalization, rituximab resistance, non-Hodgkin lymphoma
MeSH terms
Rituximab, Animals, Antibodies, Monoclonal, Cytotoxicity, Immunologic, Humans, Neoplasms, Phagocytosis, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Murine-Derived, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-1182
The paper
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M. N., Reslan, L., Gerdes, C. A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., . . . Klein, C. (2013). Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-1182

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.